Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 10/20 | 1.00 |
| ▸ | AKT2 | P31751 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30097352 | 1.00 | AKT1 (1.00) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4917931 | 0.93 | AKT1 (0.88) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4725153 | 0.93 | AKT1 (0.86) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4726182 | 0.92 | AKT1 (0.85) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4725403 | 0.92 | AKT1 (0.85) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4776861 | 0.91 | AKT1 (0.84) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4778332 | 0.91 | AKT1 (1.00) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4727021 | 0.91 | AKT1 (0.83) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4725325 | 0.90 | AKT1 (0.83) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4782194 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | claimed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250171465-A1 | AKT INHIBITORS | Stablix, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024264070-A2 | AKT INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2022187554-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022098979-A1 | METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171465-A1 | AKT INHIBITORS | PIK3CA, PIK3CD, PIK3CG | AKT1 5/4885RPS6KB1 160/4885AKT2 6/4885 |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT1 752/4885RPS6KB1 1428/4885AKT2 1098/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | AKT1 889/4885RPS6KB1 1254/4885AKT2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.